Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma
Retrospective analysis shows bridging therapy and low plasma cell burden improve ciltacabtagene autoleucel safety and efficacy in multiple myeloma.
Key Points
This research aims to evaluate the impact of bridging therapy and pre-lymphodepletion tumor burden on outcomes of ciltacabtagene autoleucel in multiple myeloma.
Conducted a retrospective study of RRMM patients treated with cilta-cel at Moffitt Cancer Center.
Assessed bridging therapy types and response criteria per International Myeloma Working Group guidelines.
Analyzed safety and efficacy outcomes based on biochemical response and plasma cell burden.
92% of patients with measurable disease achieved partial response or better after cilta-cel.
Low pre-lymphodepletion plasma cell burden was linked to improved response rates and lower adverse events.
Patients with biochemical response to bridging therapy reported lower rates of cytokine release syndrome.